Innovative system gives clients real-time access to data, offers secure
data warehousing and expedites data set conversions for electronic
KING OF PRUSSIA, PA, June 16 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, has adopted
the SAS(R) Drug Development tool to provide a centralized, integrated system
for managing, analyzing, reporting and reviewing clinical research data. SAS
Drug Development technology is being implemented across MDS Pharma Services
from the pre-clinical line of business through Phase IV to integrate worldwide
work flows. It also expedites conversion of data sets into the format
established by the Clinical Data Interchange Standards Consortium (CDISC) for
electronic regulatory submissions.
"This powerful tool will significantly improve our internal operational
efficiency and enhance our ability to provide quality, on-time service to
clients at all phases of their drug development process," said MDS Pharma
Services President David Spaight. "It allows clients to view their study data
even as it is being updated, serves as a secure repository of legacy clinical
trial data, and can convert that data into standard CDISC format for
electronic submission to regulators as part of a New Drug Application."
With the SAS Drug Development system, MDS Pharma Services can offer
medium to large pharmaceutical industry clients the ability to combine
historical clinical trial data from a variety of sources and studies, convert
it to a common format and analyze it to identify patient safety issues or new
demographic groups with commercial potential. For biotech clients, this tool
will enable the integration of all available trial datasets and their
conversion into a unified data package for due diligence, subsequent licensing
or joint venturing with a potential commercial development partner.
"Collaboration within the R&D process must include shared visibility to
information," said Jason Burke, worldwide director of Health and Life Sciences
at SAS. "The aggregation and analysis of standardized data across a compound's
lifecycle establishes a foundation for improving pharmaceutical R&D, and
organizations like MDS Pharma Services that can operationalize these
improvements have a distinct competitive advantage."
SAS Drug Development provides a centralized, integrated system for
managing, analyzing, reporting and reviewing clinical research information.
The solution enables life sciences organizations to get products to market
faster by more effectively assessing the safety and efficacy of research
compounds. The solution also facilitates collaboration across trials, phases
and therapeutic areas.
About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service on time.
We offer a full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, we apply advanced
scientific and technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research, early clinical
research (bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized cardiac
services. For more information, visit our website at www.mdsps.com.
MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ),
a global life sciences company that provides market-leading products and
services that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 5,500 highly skilled people in
29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222,
24 hours a day.
For further information:
For further information: For Investors: Kim Lee, (416) 213-4721,
email@example.com; For Media: Charlene McGrady, (610) 239-7900 ext. 231,